Immunitybio, Inc.
$67.8K 1,612 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Shimadzu Precision Instruments, Inc.
Shimadzu Precision Instruments, Inc. reported $67,895.84 across General Payments, Research, and Ownership to 21 physicians and teaching hospitals across 21 transactions.
- $67.9K Below-median payer
- All-tracks total
- 21 Below-median volume
- Transactions
- 21 Below-median reach
- Recipients
- −$4.5K
- General Payments vs PY2023
Shimadzu Precision Instruments, Inc. reported $67,895.84 across all CMS Open Payments tracks (General + Research + Ownership) to 21 physicians and teaching hospitals in Program Year 2024 - ranking #1275 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $67,895.84, averaging $3.2K per recipient.
Shimadzu Precision Instruments, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer shimadzu-precision-instruments-inc Shimadzu Precision Instruments, Inc.
$67.9K · #1275/1,925 · 0.0% industry · PY2024
- TOT $67.9K
- RANK #1275
- SHARE 0.0%
- TXN 21
- RCP 21
- CAT 3
- GEN $67.9K
- ΔGEN −$4.5K
- TOP1 69.8%
- PY 2024
Volume peers
Nearest volume peer: Immunitybio, Inc. ($67.8K)
Shimadzu Precision Instruments, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Shimadzu Precision Instruments, Inc.'s CMS-reported General Payments decreased by $4.5K (−6.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SHIMADZU PRECISION INSTRUMENTS, INC.PY2023: SHIMADZU PRECISION INSTRUMENTS, INC.PY2024: Shimadzu Precision Instruments, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $72,429.93
- PY2024
- $67,895.84
What the Data Shows for Shimadzu Precision Instruments, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Shimadzu Precision Instruments, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 3-category general-payment breakdown below at $59.9K (88.2% of General Payments, 16 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, Shimadzu Precision Instruments, Inc.'s largest category was "Consulting Fee" at $59.9K - 88.2% of General Payments.
How Shimadzu Precision Instruments, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $59.9K | 16 | 88.2% |
| Entertainment | $5.0K | 4 | 7.4% |
| Compensation for Services Other Than Consulting | $3.0K | 1 | 4.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $67,895.84 (100.0%) of $67,895.84 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Shimadzu Precision Instruments, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Brian Brown
$47,360.16 across 11 reported transactions
- 2
Stuart Smalheiser
$12,500.00 across 5 reported transactions
- 3
Michael H Rosenbloom
$5,000.00 across 4 reported transactions
- 4
Richard Grinstead
$3,035.68 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Shimadzu Precision Instruments, Inc. ranks #1275 of 1,925 by total payments (bottom 34% by spend) but is notably more concentrated than that alone would suggest -- #315 of 1,838 by HHI (top 17% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Teikoku Pharma USA, Inc. : $21.4K total payments, HHI 5368
- Avantec Vascular Corporation : $17.9K total payments, HHI 5355
- Nico Corporation : $105.7K total payments, HHI 5350
- Gebauer Company : $15.3K total payments, HHI 5350
- Affordable Pharmaceuticals, LLC : $766.7K total payments, HHI 5325
- AstraZeneca UK Limited : $15.4M total payments, HHI 5304
- Shimadzu Precision Instruments, Inc. (this company) : $67.9K total payments, HHI 5279
- AppliedVR Inc : $189.1K total payments, HHI 5275
- Partner Therapeutics, Inc. : $378.4K total payments, HHI 5272
- Gyrus ACMI, Inc. : $304.0K total payments, HHI 5269
- Boehringer Ingelheim Espana S.A. : $1.6K total payments, HHI 5266
- BioPoly LLC : $35.8K total payments, HHI 5258
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Shimadzu Precision Instruments, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Shimadzu Precision Instruments, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Shimadzu Precision Instruments, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
MIM Software Inc.
$67.1K 50 recipients
Compare payment profiles
RedHill Biopharma Inc.
$68.8K 1,502 recipients
Compare payment profiles
Icometrix NV
$67.0K 26 recipients
Compare payment profiles
Nexus CMF, LLC
$69.0K 339 recipients
Compare payment profiles
Momentis Surgical Inc.
$66.7K 21 recipients
Compare payment profiles
Put this to use
Shimadzu Precision Instruments, Inc. ranks #1275 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Shimadzu Precision Instruments, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.